New treatments like boceprevir and telaprevir promise to increase that to 60% or 70%.

FORBES: Vertex Maintains Lead Over Merck In Hepatitis C

Addenbrooke's would not say how many hepatitis patients it was treating with Boceprevir.

BBC: Glyn Huskisson

In what we would call partial responders MRK has a different definition, SVR was 40-52% for boceprevir vs. 54-59% for telaprevir.

FORBES: Vertex Edges Merck In First Round of Hepatitis C Fight

In prior relapsers, SVR was 69%-75% for boceprevir vs. 83-88% for telaprevir.

FORBES: Vertex Edges Merck In First Round of Hepatitis C Fight

Schering-Plough research head Thomas Koestler says his company is "pretty excited" by the trial results so far for its hepatitis C protease inhibitor drug boceprevir and plans to share data with regulators soon to discuss next steps.

FORBES: Magazine Article